QUOTED. 20 April 2020. Stephen Hahn.
The US FDA is still performing user-fee review activities despite the ongoing coronavirus pandemic – but how long will that be possible? Here’s what FDA Commissioner Stephen Hahn had to say recently.
“With many staff in CDRH working on COVID-19 activities related to pre-emergency use authorizations (pre-EUAs), EUAs, and immediately-in-effect guidance documents, it is possible that we will not be able to sustain our current level of performance indefinitely.” - Stephen Hahn, commissioner, US FDA
Click here for a free trial of Medtech Insight